Cargando…
Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study
BACKGROUND: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNFα) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in cli...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942680/ https://www.ncbi.nlm.nih.gov/pubmed/27352964 http://dx.doi.org/10.2196/resprot.5791 |
_version_ | 1782442460168847360 |
---|---|
author | Drabik, Attyla Sturm, Andreas Blömacher, Margit Helwig, Ulf |
author_facet | Drabik, Attyla Sturm, Andreas Blömacher, Margit Helwig, Ulf |
author_sort | Drabik, Attyla |
collection | PubMed |
description | BACKGROUND: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNFα) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in clinical trials clearly influences both response and remission rates. An unsatisfactory response to anti-TNFα medication after week 12 often leads to a discontinuation of treatment. The early prediction of clinical response could therefore help optimize therapy and potentially avoid ineffective treatments. OBJECTIVE: The aim of this study is to develop an algorithm for optimizing golimumab administration in patients with moderate to severe UC by calculating the probability of clinical response in Week 26 based on data from Week 6. METHODS: The study is designed as a prospective, single-arm, multicenter, non-interventional observational study with no interim analyses and a sample size of 58 evaluable patients. The primary outcome is the prediction of clinical response in Week 26 based on a 50% reduction in fecal calprotectin and a positive golimumab trough level in Week 6. RESULTS: Enrollment started in October 2014 and was still open at the date of submission. The study is expected to finish in December 2016. CONCLUSIONS: The early identification of patients who are responding to an anti-TNFα antibody is therapeutically beneficial. At the same time, patients who are not responding can be identified earlier. The development of a therapeutic algorithm for identifying patients as responders or non-responders can thus help prescribing physicians to both avoid ineffective treatments and adjust dosages when necessary. This in turn promotes a higher degree of treatment tolerance and patient safety in the case of anti-TNFα antibody administration. CLINICALTRIAL: German Clinical Trials Register, Deutsches Register Klinischer Studien DRKS00005940; https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005940 (Archived by WebCite at http://www.webcitation.org/6i4Xoo1sH) |
format | Online Article Text |
id | pubmed-4942680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-49426802016-07-20 Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study Drabik, Attyla Sturm, Andreas Blömacher, Margit Helwig, Ulf JMIR Res Protoc Protocol BACKGROUND: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNFα) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in clinical trials clearly influences both response and remission rates. An unsatisfactory response to anti-TNFα medication after week 12 often leads to a discontinuation of treatment. The early prediction of clinical response could therefore help optimize therapy and potentially avoid ineffective treatments. OBJECTIVE: The aim of this study is to develop an algorithm for optimizing golimumab administration in patients with moderate to severe UC by calculating the probability of clinical response in Week 26 based on data from Week 6. METHODS: The study is designed as a prospective, single-arm, multicenter, non-interventional observational study with no interim analyses and a sample size of 58 evaluable patients. The primary outcome is the prediction of clinical response in Week 26 based on a 50% reduction in fecal calprotectin and a positive golimumab trough level in Week 6. RESULTS: Enrollment started in October 2014 and was still open at the date of submission. The study is expected to finish in December 2016. CONCLUSIONS: The early identification of patients who are responding to an anti-TNFα antibody is therapeutically beneficial. At the same time, patients who are not responding can be identified earlier. The development of a therapeutic algorithm for identifying patients as responders or non-responders can thus help prescribing physicians to both avoid ineffective treatments and adjust dosages when necessary. This in turn promotes a higher degree of treatment tolerance and patient safety in the case of anti-TNFα antibody administration. CLINICALTRIAL: German Clinical Trials Register, Deutsches Register Klinischer Studien DRKS00005940; https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005940 (Archived by WebCite at http://www.webcitation.org/6i4Xoo1sH) JMIR Publications 2016-06-28 /pmc/articles/PMC4942680/ /pubmed/27352964 http://dx.doi.org/10.2196/resprot.5791 Text en ©Attyla Drabik, Andreas Sturm, Margit Blömacher, Ulf Helwig. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 28.06.2016. https://creativecommons.org/licenses/by/2.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/ (https://creativecommons.org/licenses/by/2.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included. |
spellingShingle | Protocol Drabik, Attyla Sturm, Andreas Blömacher, Margit Helwig, Ulf Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title | Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title_full | Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title_fullStr | Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title_full_unstemmed | Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title_short | Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study |
title_sort | early monitoring of response (more) to golimumab therapy based on fecal calprotectin and trough serum levels in patients with ulcerative colitis: a multicenter prospective study |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942680/ https://www.ncbi.nlm.nih.gov/pubmed/27352964 http://dx.doi.org/10.2196/resprot.5791 |
work_keys_str_mv | AT drabikattyla earlymonitoringofresponsemoretogolimumabtherapybasedonfecalcalprotectinandtroughserumlevelsinpatientswithulcerativecolitisamulticenterprospectivestudy AT sturmandreas earlymonitoringofresponsemoretogolimumabtherapybasedonfecalcalprotectinandtroughserumlevelsinpatientswithulcerativecolitisamulticenterprospectivestudy AT blomachermargit earlymonitoringofresponsemoretogolimumabtherapybasedonfecalcalprotectinandtroughserumlevelsinpatientswithulcerativecolitisamulticenterprospectivestudy AT helwigulf earlymonitoringofresponsemoretogolimumabtherapybasedonfecalcalprotectinandtroughserumlevelsinpatientswithulcerativecolitisamulticenterprospectivestudy |